Treatment: Campylobacter: erythromycin 10 mg kg to 500 mg or erythromycin ethyl succinate 20 mg kg to 800 mg orally 6 hourly for 5-7 d; norfloxacin 10 mg kg to 400 mg orally 12 hourly for 5 d 13% require treatment, though treatment in all cases shortens symptomatic period, carriage and shedding; Guillain-Barr syndrome possible sequela ; Staphylococcus aureus: i.v. cloxacillin + oral neomycin Bacteroides: metronidazole NECROTISING ENTEROCOLITIS ENTERITIS NECROTICANS, PIG-BEL ; : common in Papua New Guinea and China Agent: Clostridium perfringens type C, Clostridium butyricum Diagnosis: severe abdominal pain developing up to 4 after a protein meal, often associated with vomiting, abdominal distension and either mild diarrhoea with blood or constipation; culture of surgical specimens and typing of isolate Treatment: surgical resection of affected length of intestine; if surgery impossible, metronidazole 500 mg child: 7.5 mg kg ; i.v. 8 hourly or 1 g child: 500 mg ; rectally 8 hourly NEONATAL NECROTISING ENTEROCOLITIS: 1-7.5% of neonates; significantly higher rates in infants given amoxycillinclavulanate Agents: Escherichia coli, Klebsiella pneumoniae Diagnosis: clinical; X-ray pneumotosis intestinalis platelet count 100 000 ? L Treatment: withdrawal of enteric feeding; oral and parenteral aminoglycoside Prophylaxis: sodium deoxycholate PSEUDOMEMBRANOUS COLITIS AND ANTIBIOTIC-ASSOCIATED DIARRHOEA: 10% of infective diarrhoea in adults Agents: Clostridium difficile necrotising enterocolitis, 90% of pseudomembranous colitis, 30% of antibiotic-associated diarrhoea ; , Klebsiella oxytoca hemorrhagic colitis ; , Staphylococcus aureus antibiotic-associated diarrhoea ; Diagnosis: Clostridium difficile: abdominal pain, fever, nausea, vomiting, diarrhoea; faeces may be blood-stained; history of antibiotic treatment especially clindamycin and third generation cephalosporins ; or antineoplastic chemotherapy; microtitre cytotoxicity toxin assay of faeces 5 d old human foreskin fibroblast or WI-38 cells; read after 4 and 24 h; sensitivity 97-100%, specificity 95% culture of faeces sensitivity 89%, specificity 74% counterimmunoelectrophoresis of faeces antiserum to toxin absorbed with cells; sensitivity 41-100%, specificity 78100% ELISA Premier Toxin A and B most sensitive commercial kit latex agglutination sensitivity 88-91%, specificity 91-99% ; Staphylococcus aureus: profuse watery diarrhoea with dehydration; faeces culture Treatment Clostridium difficile ; : cessation of antibiotic treatment; metronidazole 10 mg kg to 400 mg orally 8 hourly for 7-10 d Metronidazole Intolerant: bacitracin 20 000-25 000 U orally 6 hourly for 7-10 d Unresponsive, Relapsing or Severe: vancomycin 3 mg kg to 125 mg orally 6 hourly for 7-10 d Severely Ill with Toxic Megacolon: metronidazole 12.5 mg kg to 500 mg i.v. 12 hourly + vancomycin 12.5 mg kg to 500 mg orally or via nasogastric tube 6 hourly for 10 d Prophylaxis: Saccharomyces boulardii HAEMORRHAGIC COLITIS Agent: shigatoxin-producing Escherichia coli 3% of bloody diarrhoea; incidence 3 100 000 in USA 110, 000 estimated total cases, 85% foodborne, 1% of foodborne related deaths; 3% of foodborne disease outbreaks, with 4% of cases and 28% of deaths; undercooked meat ground beef ; or poultry, unpasteurised milk or juice, unpasteurised soft cheeses, unchlorinated water supplies, animal contact at petting zoo, farm animal hides; most sporadic cases from environment mainly serotype O157: H7; cases due to O111: H8 in Australia; also O173: H55 and O166 may lead to development of haemolytic uraemic syndrome or thrombotic thrombocytopenic purpura, particularly in children 15 y and adults 65 y hypochlorhydria and coincidental antibiotics significant risk factors ; Diagnosis: severe, often bloody, diarrhoea, abdominal pain and vomiting following ingestion of undercooked beef, unpasteurised milk or juice, raw fruits and vegetables, salami, salad dressing, contaminated water; incubation period 1. Continue with systemic amoxicillin clavulanic acid 625 mg every 8 h ; for 3 weeks and then with flucloxacillin 500 mg every 8 h ; for 4 weeks. A marked reduction of the inflammatory signs was observed but only during treatment periods.
COMPARISON OF LOCAL AND GLOBAL ANGULAR INTERPOLATION APPLIED TO SPECTRAL-SPATIAL EPR IMAGE RECONSTRUCTION Kang-Hyun Ahn and Howard J. Halpern Department of Radiation and Cellular Oncology, University of Chicago Medical Center, Center for EPR Imaging In Vivo Physiology, Chicago, IL 60637 Email: khahn uchicago Spectral-spatial images reconstructed from a small number of projections suffer from streak artifacts that are seen as noise, particularly in the spectral dimension. Interpolation in projection space can reduce artifacts in the reconstructed images. The reduction of background artifacts improves lineshape fitting. In this work, we compared the performances of angular interpolation implemented using linear, cubic B-spline and sinc methods. Line width maps were extracted from 4D EPR images of phantoms using spectral fitting to evaluate each interpolation method and its robustness to noise. Results from experiment and simulation showed that the cubic B-spline angular interpolation was preferable to either sinc or linear interpolation methods. Support by NIH P41 EB002034 is gratefully acknowledged!

Cephalexin Keflex ; Capsule: 250 mg, 500 mg Powder for oral suspension: 100 mg mL, 125 mg 5 mL, 250 mg 5 mL Tablet: 250 mg, 500 mg, 1 g Tablet: 500 mg Chloroquine Aralen ; Tablet: 250 mg, 500 mg Ciprofloxacin Cipro, Ciloxan ; Injection: 200 mg, 400 mg Solution, ophthalmic: 0.3% Suspension, oral: 5 gm 100 mL, 10 gm 100 mL Tablet: 100 mg, 250 mg, 500 mg, 750 mg Clarithromycin Biaxin ; - RESERVE USE Granules for oral suspension: 125 mg 5 mL, 250 mg 5 mL Tablet, film coated: 250 mg, 500 mg Clindamycin Cleocin, Cleocin T ; Capsule: 75 mg, 150 mg, 300 mg Gel, topical: 1% [10 mg g] Granules for oral solution: 75 mg 5 mL Injection: 150 mg mL Lotion: 1% [10 mg mL] Solution, topical: 1% [10 mg mL] Cloxaccillin Cloxapen, Tegopen ; Capsule: 250 mg, 500 mg Powder for oral suspension: 125 mg 5 mL Delavirdine DLV, Rescriptor ; Tablet: 100 mg, 200 mg Dicloxacillin Dycill, Dynapen, Pathocil ; Capsule: 125 mg, 250 mg, 500 mg Powder for oral suspension: 62.5 mg mL Didanosine ddI, Videx ; Capsule, delayed release: 250 mg Powder for oral solution: 100 mg, 167 mg, 250 mg, 375 mg, 2 gm, 4 gm Tablet, chewable: 25 mg, 50 mg, 100 mg, 150 mg, 200 mg. CEPHALOSPORINS FIRST GENERATION Cefadroxil Cephalexin SECOND GENERATION Cefaclor Cefprozil Cefuroxime THIRD GENERATION Cefixime ERYTHROMYCINS Azithromycin Clarithromycin Erythromycin Base Erythromycin Ethylsuccinate Erythromycin Stearate Erythromycin Sulfisoxazole FLUOROQUINOLONES Ciprofloxacin Levofloxacin Moxifloxacin # Ofloxacin MISCELLANEOUS Clindamycin Furozolidone Vancomycin PENICILLINS Amoxicillin Amoxicillin Pot Clavulanate Ampicillin Dicloxacillin Penicillin VK SULFONAMIDES Sulfadiazine Sulfamethoxazole Trimethoprim Sulfisoxazole TETRACYCLINES Doxycycline Minocycline Tetracycline URINARY TRACT MEDICATIONS Methenamine Mandelate Duricef Keflex Ceclor Cefzil Ceftin Suprax Zithromax, Zmax Biaxin, Biaxin XL Ery-Tab, Eryc E.E.S Erythrocin Pediazole Cipro Levaquin Avelox # Floxin Cleocin Furoxone Vancocin Amoxil Augmentin Polycillin Dynapen Pen Vee K Sulfadiazine Bactrim, Bactrim DS Gantrisin Vibramycin Minocin Sumycin Mandelamine Capsule, Suspension Capsule, Suspension Capsule, Suspension Suspension Tablet, Suspension Suspension Tablet, Suspension Tablet, Suspension Tablet, Capsule Tablet, Suspension Tablet Suspension Tablet, Suspension Tablet Tablet Tablet Capsule, Suspension Tablet, Suspension Capsule Capsule, Suspension Tablet, Suspension Capsule, Suspension Capsule, Suspension Tablet, Suspension Tablet Tablet, Suspension Tablet, Suspension Capsule Capsule Capsule Tablet, Suspension and cromolyn. Your E-Ticket, a summary of your current donation balance and medical form standing which you will receive on Friday, September 7, 2007. If you receive additional online donations between the time you received your ETicket and Event Eve, please print an updated E-Ticket and bring it with you to Event Eve. To do this, sign on to the Avon Walk website avonwalk ; and from your "My Avon Walk" page, click "Print Your Event Eve E-Ticket. Cloxacillin is used to treat a wide variety of bacterial infections and danocrine. Site location: home drug and alcohol information addictive drugs legal drugs drug and alcohol information - legal drugs - legal drugs a legal drug is not necessarily safe or non-addictive.
Sl. No Drug Code Name of the Drug & Strength Packing Unit Appoximate Quantity Required For one year -5 120000 vial. 320000 cap. 640000 tab and ddavp.
OBJECTIVE: To employ a carefully structured dose optimization program within a large integrated healthcare system to maximize potential drug cost savings. SETTING: Provider Service Network Boston, MA ; PRACTICE INNOVATION: A dosage optimization intervention utilizes pharmacy claims data to prospectively identify patients receiving multiple units per day of a lower strength, once-daily medication and provides clinicians a tool to switch these patients to a regimen that is an equivalent daily dose given as a single unit once daily. Performing this intervention with chronic once-daily medications that are available in multiple strengths with comparable pricing among these strengths can yield significant drug cost savings. Erythromycin and other macrolides TJ03. Flucloxacillin Ibuprofen Indomethacin Intravenous anaesthetics Iodine or iodide TJ002 TJ560 TJ565 TJ83z TJ281 and stimate.
DERMATOP .33 DERMOTIC.38 desal-ii.40 desipramine hcl .17 desmopressin acetate.35 desonide .33 desoximetasone .33 DESOXYN .27 despec.40 despec sr.40 desquam-e .29 desquam-x .29 DETROL.32 DETROL LA .32 dexamethasone.32 dexamethasone intensol .32 dexaphen sa.42 dexasol .38 dexasporin .13 dexchlorpheniramine malea.42 DEXPAK.32 DEXRAZOXANE .44 dextroamphetamine sulfate .27 dextrose sodium chloride.44 dextrose lactated ringer.46 dextrostat.27 d-feda ii .40 dg 200 .43 DHT .47 DHT INTENSOL.47 diabetic tussin c liquid .39 dialyte 2.5% dextrose pat.28 DIAMOX .37 dianeal low calcium 2.5%.28 dianeal pd dex .28 di-atro.30 diatx zn tablet.39 diazepam tablet .23 DIBENZYLINE.26 diclofenac potassium.11, 19 diclofenac sodium .11, 19 diclofenac sodium er.11, 19 diclofenac sodium sr .11, 19 diclofenac sodium xr.11, 19 dicloxacillin sodium.15 dicyclomine hcl.30 didanosine .22 DIDRONEL IV.34 DIFFERIN.28 difil g forte .43 DIFIL-G .43 diflorasone diacetate .33 diflunisal .11, 19 Digestants.31 digitek .26. Evident between neighboring cells Fig. 6C ; . The apical surface of the most superficial cells was covered with a glycocalyx-like material Fig. 6D ; . SEM examination of the normal corneal, conjunctival, and oral cells showed that the surface morphology of the corneal epithelial cells was different from that of the other cell types. The corneal epithelial cells revealed a continuous layer of flat squamous polygonal epithelial cells with an average size of 28.4 10.0 m with distinct surface microvilli Fig. 7A ; . The conjunctiva consisted of smaller polygonal epithelial cells with an average size of 12.3 2.3 m mixed with numerous goblet cells Fig. 7C ; . The oral mucosal samples Fig. 7E ; cells had an average size of 27.5 8.4 m, and their apical surfaces had long parallel ridge-like structures quite different from the microvilli on the corneal epithelial cells. TEM examination of the normal corneal, conjunctival, and oral cells showed that the corneal epithelial cells could be easily distinguished from the other cell types by their ultrastructure. The corneal epithelial cells consisted of five to six layers of well-stratified epithelium Fig. 7B ; , appeared healthy, and were differentiated into basal columnar cells, suprabasal cuboid wing cells, and flat squamous superficial cells. The rabbit conjunctiva could be easily identified by the presence of numerous goblet cells Fig. 7D ; . The oral samples Fig. 7F ; had many more cell layers than were present in the normal corneal epithelial cell layer and desmopressin.

Order generic Cloxacillin P.o. i.v. Benzyl penicillin i.v. Ceftazidime i.v. Ciprofloxacin p.o. Cotrimoxazole p.o. or i.v. trimethoprim + sulphamethoxazole ; Doxycycline p.o. Erythromycin i.v. Flucloxacillin i.v. Gentamicin i.v. Dextrose In Sodium Chloride 5% 0.45% Solution Dextrose In Water 10% Solution Dextrose In Water 4.3-5% Solution Dextrose In Water 5% Solution Dextrose In Water Hypertonic ; 50% Solution Dialysis Sol. Peritoneal W Dextrose 1.5% Solution Diazepam Ic ; 5 Mg Ampoule Diazepam Ic ; 10 Mg Tab-Cap Diazepam Ic ; 2 Mg Tab-Cap Diazepam Ic ; 5 Mg Tab-Cap Diclofenac Sodium 25 Mg ml Ampoule Diclofenac Sodium 0.1% Opht Drop Diclofenac Sodium 25 Mg Tab-Cap Diclofenac Sodium 50 Mg Tab-Cap Diclofenac Sodium Sustained-Release ; 75 Mg Tab-Cap Dicloxacillin 250 Mg Tab-Cap Dicloxacillin 500 Mg Vial Didanosine 8.33 Mg ml Suspen Didanosine Chewable ; 100 Mg Tab-Cap Didanosine 100 Mg Tab-Cap Didanosine 150 Mg Tab-Cap Didanosine 200 Mg Tab-Cap Didanosine 25 Mg Tab-Cap Didanosine 400 Mg Tab-Cap Digoxin 0.25 Mg ml Ampoule Digoxin 0.05 Mg ml Solution Digoxin 0.125 Mg Tab-Cap Digoxin 0.25 Mg Tab-Cap Diltiazem Hcl 60 Mg Tab-Cap Dimenhydrinate 100 Mg Suppos Dimenhydrinate 50 Mg Suppos Dimenhydrinate 50 Mg Tab-Cap Dimenhydrinate 50 Mg ml Vial Dinoprostone 10 Mg ml Vial Diphenhydramine 50 Mg Tab-Cap Diphenoxalate + atropine Sulfate 2.5mg + .025mg Tab-Cap Diphtheria Antitoxin 10, 000 Iu Ampoule Dipivefrine 0.1% Opht Drop Dobutamine 12.5 Mg ml Vial Dopamine Hcl 40 Mg ml Ampoule Dorzolamide Chlorhydrate 2% Opht Drop Doxorubicin Hcl 10 Mg Vial Doxorubicin Hcl 50 Mg Vial and decadron. How does Wisconsin Medicaid Cover this?, for example, cloxacillin sod.

Cheap Cloxacillin When the activity of β -lactamase i was measured in 3– 2 m guanidinium chloride the rates of hydrolysis of methicillin or cloxacillin but not benzylpenicillin ; were greatly reduced and dexamethasone. A randomised trial comparing flucloxacillin with clindamycin for the treatment of adults with cellulitis at Auckland Hospital Associate Professor Mark Thomas, Associate Professor Rod Ellis-Pegler, Dr Andrew Woodhouse, Dr Simon Briggs, Dr David Holland, Dr Mark Jones, Department of Molecular Medicine and Pathology, and Clinical Trials Research Unit, Faculty of Medical and Health Sciences, University of Auckland and Adult Infectious Diseases Unit, Auckland City Hospital This project commenced in early 2003 when the principal investigator, Dr Mark Thomas, began a one year sabbatical based in Auckland. A total of 69 patients with cellulitis were referred for consideration of entry into the trial. This number was less than anticipated for a variety of reasons. Commencement of enrolment was delayed by administrative considerations, and patients frequently presented with cellulitis at times when enrolment could not be performed because of difficulties with dispensing of study drugs i.e. after 4pm or during weekends ; . Eight patients declined entry and 24 patients were ineligible for entry for a variety of reasons. A total of 45 patients were entered into the trial. Unfortunately it was not possible to continue recruiting patients into the trial once the period of sabbatical was finished, at the end of 2003, due to time pressure from Dr Thomas' other commitments. The trial was therefore stopped without enrolling sufficient patients to allow any hope of a statistically significant result being achieved. The decision was made to not break the trial code, but to await the situation where another person would have time to continue enrolment into the trial. We are hopeful that recruitment can begin again at the start of 2006 when we expect that a senior registrar Dr Steve Ritchie ; begins a period of research on a variety of topics in the Adult Infectious Diseases Unit at Auckland City Hospital. We are hopeful that with his help we can continue to recruit patients to achieve a total enrolment of over 100 patients. While the code for treatment allocation has not been broken, the experience with the patients in the trial was that no patient failed treatment or required to be withdrawn from the trial, other than two patients who had alternative diagnoses ischaemic foot in one patient and septic arthritis of the first MCP joint in the other ; and two patients with cellulitis shown to be due to MRSA. The impression of the principal investigator is therefore that completion of the trial might be expected to show equivalence between oral clindamycin and intravenous followed by oral flucloxacillin for the treatment of cellulitis. This would be an important finding. Clarithromycin .6 clemastine fumarate .33 CLEOCIN.29 CLEOCIN PALMITATE .7 CLEOCIN PHOSPHATE IN D5W.7 CLIMARA .29 CLIMARA PRO.29 clinda-derm .19 clindamax .29 clindamycin HCl.7 clindamycin phosphate.7, 19 clobetasol e.21 clobetasol propionate .21 CLOBEX .21 CLOLAR .9 clomipramine HCl .14 clonidine HCl .16 clotrimazole .5 clotrimazole-betamethasone.20 cloxacilpin sodium .7 clozapine.14 codeine sulfate.12 COGENTIN INJECTION .11 COLAZAL .26 colchicine.28 COLESTID.18 col-probenecid.28 COLY-MYCIN S.22 colytrol.25 COMBIPATCH .29 COMBIVENT .34 COMBIVIR .5 COMPAZINE .25 compro.25 COMTAN .11 COMVAX.28 co-natal fa .36 CONDYLOX.19 CONEX .33 constulose .26 COPAXONE.12 copd .35 CORDRAN TAPE.20 COREG .16 cormax .21 cortane-b .22 cort-biotic .22 cortic.22 cortic-nd .22 CORTIFOAM.26 cortisone acetate .23 CORTISPORIN-TC .22 cortomycin .22, 32 CORTONE ACETATE .23 and divalproex.

Sl. No. 1. 2. 3. Antibiotic Amikacin 30g disc Azithromycin 15g disc Cephalaxine 30g disc Streptomycin 10g disc Ampicillin 10g disc Nalidixic acid Na 30g disc Ciprofloxacin 10g disc Cefactor 30g disc Rifampicin 5g disc Cl9xacillin 1g disc Chloroamphenico C 30g disc Erythromycin 30g disc Oxacillin 5g disc Neomycin 30g disc Gentamicin 10g disc Vancomycin 30g disc Isolat e 4 S Isolate 8 R R Isolate 9 S S Isolate 99 S R Isolat e 108 S S R Isolate 112 S S R Isolate 129 S S R Isolate 123 S R R Isolate 124 R R R. They are all available in several different strengths and doses as tablets and tolterodine and cloxacillin, for instance, cloxacilljn breastfeeding.
Also during 2000, biovail issued 27, 000 additional common shares related to the acquisition of fuisz with a fair value of $386, 00 the excess of the cash settlement of the contract over the amount of the reserve and the issuance of the common shares resulted in a charge of $7, 460, 000 to net income in 200 effective january 4, 2000 , biovail entered into an agreement to sell all of the issued share capital of a subsidiary of fuisz, clonmel healthcare limited clonmel ; , a pharmaceutical and antibiotic manufacturer and distributor located in ireland, for proceeds of $20, 000, 00 biovail recognized no gain or loss on this transaction as clonmel was included at its fair value in the determination of the net assets of fuisz acquired. We hope your visits to the great out doors will be enjoyable, and they will be if you avoid the hazards that may be present. One hazard that you should be aware of is a disease that can be contracted from drinking untreated "natural" water. It is an intestinal disorder called GIARDIAS gee-ar-dye-a-sis ; . It can cause severe discomfort. The disease is caused by a microscopic organism, Giardia Lamblia. The cystic form of Giardia may be found in Mountain streams and lakes across North America. Natural waters may be clear, cold and clean running. They may even smell and taste good. You may also see wildlife drinking from these sources without any hesitation. All of these signs sometimes lead people to thinking that the natural water is safe for drinking. The most certain treatment to eliminate Giardia is to boil your water for at least one minute at a rolling boil ; . At higher altitudes you should maintain the boil for three to five minutes for an added margin of safety. Iodine or chlorine tablets or drops work well against waterborne bacteria. They are not considered y are not recommended in a routine disinfection Micro filters available on the market are advertised to kill Giardia. You should investigate these products carefully and thoroughly understand their care and use before using a micro water filter. The new filters can also filter out viruses too and gliclazide.

BETA lactams Charm BSDA Tablet - Beta lactams Charm II Tablet Competitive Charm II Tablet Quantitative Charm II Tablet Sequential Charm SL Beta lactams Charm SL-6 Delvotest P 5 Pack Beta lactams Delvotest P Delvotest P Mini Delvotest SP Delvotest SP Mini Idexx New Snap Penzyme Milk Test Beta lactams Snap Visual ; - Beta lactams CLOXACILLIN Charm II Tablet Quantitative SULFONAMIDES Agri-Screen for Sulfonamides * , * Charm II Tablet Competitive 0 420 0 0 197 401 0 1 197 821 0 1 0.000% 0.122% 0 0 7 0 0.000% 14, 794 1, 0 7, 717 3, 0 521 0 3 22, 361 0 2, 125 3, 0 2, 367 0 0 25 143 1 0 4 37, 155 0 0 7 0.170% 0.050% 0.000% 0.094% 0.268% 0.185% 0.000% 0.113% 0.000% 0.000. Journal of the Hong Kong Geriatric Society culture was taken, this subsequently produced no growth. She was treated with elevation of the affected limb, ampicillin and cloxacillin intravenously. Venography performed 2 days later revealed clots in the axillary vein Fig. 1 ; . The subclavian vein was not opacified. Tufts ofcollaterals were visualized Fig. 2 ; . The diagnosis was axillary and subclaviar, vein thrombosis. CT scan of throax was also performed and showed thrombosis of the right internal jugular and right brachiocephalic vein Fig. 3 ; . The patient was anticoagulated with intravenous heparin for 5 days then warfarin orally. After anticoagulation her facial and right upper extremity oedema gradually subsided over a week. Screening tests were done to look for underlying malignancy. These included abdominal ultrasonography. sputum for cytology, stool for occult blood x 3. Results were all negative. Her condition was subsequently stable. She was mobilized over the next two weeks and discharged on: Warfarin 1.5mg qd, frusemide 80mg om. chlorpromazine 25mg N, terbutaline and potassium supplement. At discharge her prothrombin time was 33 13. I NR was 2.7. She was followed up in the geriatric day hospital for monitoring of anticoagulation and rehabiliation. Warfarin was stopped after three months. At the sixth month of follow-up she was free from recurrence of deep venous thrombosis. No underlying malignancy was evident. Discussion Deep venous thrombosis of the upper extremity is uncommon. In a six year review, thrombosis occurring in the upper extremity accounted only for 4% 33 cases ; of the 804 cases of deep venous thrombosis diagnosed2. The same authors reviewed eight other series since 1949, and found that catheterinduced thrombosis is becoming a major cause. In the three most recent series, catheters caused 2439% of all incidences of deep venous thrombosis of the upper extremity. The risk of thrombosis developing from central venous cannulation is affected by various factors, including: 1. circumferential size ofthe cannula risk increases with catheter size ; : 2. multiple venipuncture attempts: 3. the composition of infusate, e.g. pH, amino-acid concentration: and 4. the duration of catheter placement2. Regarding the duration of placement, a necropsy series of 32 patients who died with a catheter in-situ in the pulmonary artery found that, of the 17 patients with thrombosis on postmortem examination, the risk was almost 100% higher in those with catheter placed for over 36 hours, compared to the short duration group 73.3% 46 vs 35.3% ; 3. In this respect the case reported here is unusual, in that the cannula was in place only for 6 hours. The thrombogenicity of catheter material is receiving much attention in recent years. Borow and Crowley-1 used Chromium-51 labelled platelets to study adhesion to various catheters in vitro, and found good correlation with in vivo methods. In their study. the least thrombogenic was a hydromercoated polyurethane catheter. the catheter with the next lowest labelled-platelet count was polyvinylchloride by Deseret, a silicone catheter made by Sorensen, and a Teflon catheter made by Deseret the same material as that used in this patient ; . The two most thrombogenic catheters were: a polyurethane catheter by Arrow and a silicone catheter made by Travenol. Platelet deposition on tested-catheter occurred as early as 30 minutes and peaked at 3-4 hours. Platelet adhesion was followed by platelet aggregation and then laying down of a fibrin sheath around the catheter. Virtually 100% of subclavian catheters were found to have fibrin sheath on post-mortem examination: of these only a minority would progress to thrombosis up to 28% ; . even then the thrombosis might be subclinical. Complete venous occlusion was reported to occur in some 6% 4. The average time between catheter insertion and development of clinical thrombosis was 9 days5. Complications of deep venous thrombosis of the upper extremity are significant. Septic thromboplebitis occurred in 8 of patients in one series, leading to 1 death due to septicemia5. Pulmonary embolism occurred in approximately 12% in most series2. This can occur as early as 4-5 days after cannulation. In retrospect this patient's episode of tachypnea, transient hypotension, metabolic acidosis with respiratory alkalosis, and atypical pattern of cardiac enzyme increase may all be explained by pulmonary embolism, although no clinical evidence of deep venous thrombosis was detectable at that point. Other complications of deep venous thrombosis of the upper extremity include: Loss of central venous access, extravasation of infusate, venous gangrene and superior vena caval syndrome. Superior vena caval syndrome is a rare presentation. occurring only in 1 of cases in one series5. The features in this patient were interestingly unilateral. as only the right brachiocephalic vein was thrombased, the left brachiaocephalic vein and the superior vena cava proper being spared. Venography is the definitive test in the investigation of suspected deep venous thrombosis of the upper extremity. However, the contrast material may aggravate existing thrombosis. A significant and cromolyn.
CYHEXATINE ARTIFACT TEBUFENPYRAD-TMS N- 4-tert-butylbenzyl ; -4-chloro-3-ethyl-1-methyl-N trimethylsilyl ; -1H-pyrazole-5-carboxamide HEXACHLOROPHENE 3, 4, 6-trichloro-2- ; phenol 7-BROMO-ACETYLMORPHINE 1S, 5R, ; 13~.0~5, 17~.0~7, 18~]octadeca7 ; , 8, 10, 15-tetraen-14-yl acetate 13~.0~5, 17~.0~7, ; , 8, 10, 15-tetraen-14-yl acetate CLOMIFENE 2 N, Ndiethylethanamine 2 N, Ndiethylethanamine N- 2- ethyl ; -N, Ndiethylamine FLOCTAFENINE 2, 3-dihydroxypropyl 2- benzoate CARVEDILOL 1- 9H-carbazol-4-yloxy ; -3- 2-propanol NANDROLONPHENYLPROPIONATE 3-oxoestr-4-en-17-yl 3-phenylpropanoate AMLODIPIN-METABOLITE 1 MEPINDOLOL-2TMS N-isopropyl trimethyl ; -N- silanamine N-isopropyl-N N- trimethylsilyl ; amine STRYCHNIN 1-TMS 10-[ trimethylsilyl ; oxy]-10, 11-didehydrostrychnidine STRYCHNIN 2-TMS 10-[ trimethylsilyl ; oxy]-10, 11-didehydrostrychnidine STRYCHNIN 3-TMS 10-[ trimethylsilyl ; oxy]-10, 11-didehydrostrychnidine CHLORODANE 1 3, CHLORODANE 2 1, 3, FLUCLOXACILLINE ARTIFACT 4 3- 2-chloro-6-fluorophenyl ; -N- 3, ; -4-isoxazolecarboxamide TRIFLUOPERAZINE 10-[3- 4-methyl-1-piperazinyl ; propyl]-2- trifluoromethyl ; -10Hphenothiazine ETHYLBISCOUMACETATE ethyl bis 4-hydroxy-2-oxo-2H-chromen-3-yl ; acetate AMLODIPINE 3-ethyl 5-methyl 2-[ ; methyl]-4- 2-chlorophenyl ; 6-methyl-1, 4-dihydro-3, 5-pyridinedicarboxylate ACEBUTOLOL-TMS N- 3-acetyl-4- phenyl ; butanamide TELODRINE 1, 3, 5, OCTACHLOROCAMPHENE 1, 2, TRICHLOROPHENIDINE 1, 3-bis 3-chlorophenyl ; -2- trichloromethyl ; imidazolidine!